Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Clark M. Reader seeks clarification on hand-foot skin reaction. Clin J Oncol Nurs. 2008 Jun 1;12(3):395.